---
title: "RACOVIR registry: Oral anticoagulation in primary care patients with non‑valvular atrial fibrillat"
id: "medrxiv-1-oral-anticoagulation-registry-in-patients-with-atrial-fibrillation-treated-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-oral-anticoagulation-registry-in-patients-with-atrial-fibrillation-treated-in"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1?rss=1"
published_at: "2026-08-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# RACOVIR registry: Oral anticoagulation in primary care patients with non‑valvular atrial fibrillat
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-oral-anticoagulation-registry-in-patients-with-atrial-fibrillation-treated-in
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1?rss=1)
- **Published At:** 2026-08-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This observational, descriptive registry (RACOVIR) evaluated management of patients with **non‑valvular atrial fibrillation** (NVAF) receiving oral anticoagulation in Spanish primary care. - The study included 1,901 patients: 428 on **vitamin K antagonists (VKAs)** and 1,473 on **direct oral anticoagulants (DOACs)**. - Patients on VKAs were older and had a higher prevalence of hypertension compared with those on DOACs. - Mean reported treatment duration was 7.6 years for VKA-treated patients and 3.8 years for DOAC-treated patients. - Anticoagulation control among VKA users: 56.2% by direct method and 59.0% by Rosendaal method achieved good control. - Patients on DOACs reported higher treatment satisfaction across domains measured by the ACTS questionnaire, including perceived benefits and lower daily‑life impact. - Event incidence rates (per 1,000 person‑years) reported were higher with DOACs versus VKAs for stroke (1.75; 95% CI 1.05–2.92), ischemic stroke (1.78; 95% CI 1.06–3.00), acute myocardial infarction (1.64; 95% CI 0.97–2.79), and major bleeding (3.68; 95% CI 1.81–7.46). - Authors note that differences in patient profiles and treatment duration by anticoagulant type may partly explain observed outcome differences despite greater satisfaction with DOACs. - The study is a preprint and not peer reviewed; ethical approval was obtained from the Ethics Committee for Research with Medicines of Hospital Clínico San Carlos. - Study data are available at the SEMERGEN RACOVIR repository link provided by the authors.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=A6x16A2m967H8r0LFzzGjFm2VPcq5CKjC7ZwprUp2gQ-1785751226.196575-1.2.1.1-6dqVcKQeU9h8OTuDBC5lC3ezEoiDa0xrl471CK6rkRs) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Oral anticoagulation registry in patients with atrial fibrillation treated in Primary Care in clinical practice. The RACOVIR Study. Jose Polo Garcia, [ View ORCID Profile](http://orcid.org/0000-0002-2575-1236)Rafael Manuel Mico Perez, Esperanza Garcia Gabriel, Juan Carlos Romero Vigara, Antonio Segura Fragoso, Aurora García Lerín, [ View ORCID Profile](http://orcid.org/0000-0001-7450-0452)Valeria Kopytina, Carlos Santos Altozano doi: https://doi.org/10.64898/2026.07.30.26358911 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jose Polo Garcia 1 Servicio Extremeño de Salud, SEMERGEN Foundation; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jose%2BPolo%2BGarcia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Polo%20Garcia%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJose%2BPolo%2BGarcia%2B) Rafael Manuel Mico Perez 2 Conselleria de Sanitat Valencia. SEMERGEN Foundation; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rafael%2BManuel%2BMico%2BPerez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mico%20Perez%20RM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARafael%2BManuel%2BMico%2BPerez%2B) * [ORCID record for Rafael Manuel Mico Perez](http://orcid.org/0000-0002-2575-1236 "Open in new tab") * For correspondence: rafaelmmicoperez@gmail.com Esperanza Garcia Gabriel 3 Servicio Extremeño de Salud; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Esperanza%2BGarcia%2BGabriel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garcia%20Gabriel%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEsperanza%2BGarcia%2BGabriel%2B) Juan Carlos Romero Vigara 4 Servicio Aragonés de Salud: Servicio Aragones de Salud; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Juan%2BCarlos%2BRomero%2BVigara%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Romero%20Vigara%20JC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJuan%2BCarlos%2BRomero%2BVigara%2B) Antonio Segura Fragoso 5 Universidad de Castilla-La Mancha; SEMERGEN Foundation; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Antonio%2BSegura%2BFragoso%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Segura%20Fragoso%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAntonio%2BSegura%2BFragoso%2B) Aurora García Lerín 6 Madrid Salud; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aurora%2BGarc%C3%ADa%2BLer%C3%ADn%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garc%C3%ADa%20Ler%C3%ADn%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAurora%2BGarc%25C3%25ADa%2BLer%25C3%25ADn%2B) Valeria Kopytina 7 SEMERGEN Foundation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Valeria%2BKopytina%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kopytina%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AValeria%2BKopytina%2B) * [ORCID record for Valeria Kopytina](http://orcid.org/0000-0001-7450-0452 "Open in new tab") Carlos Santos Altozano 3 Servicio Extremeño de Salud; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Carlos%2BSantos%2BAltozano%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Santos%20Altozano%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACarlos%2BSantos%2BAltozano%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1270177/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1270177/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1270177/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1270177/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1270177/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objectives: To assess how patients with non-valvular atrial fibrillation (NVAF) receiving oral anticoagulants are managed in routine primary care practice in Spain. Methods: This observational, descriptive study included patients with NVAF treated with oral anticoagulants for at least 6 months before enrolment and managed in primary care settings in Spain. The Barthel and ACTS questionnaires were administered to evaluate functional autonomy and treatment satisfaction, respectively. Results: A total of 1,901 patients were included: 428 received vitamin K antagonists (VKAs) and 1,473 direct oral anticoagulants (DOACs). Compared with patients receiving DOACs, those treated with VKAs were significantly older and had a higher prevalence of more hypertension. Mean treatment duration was 7.6 years for VKAs and 3.8 years for DOACs. Among patients receiving VKAs, 56.2% and 59.0% achieved good anticoagulation control according to the direct and Rosendaal methods, respectively. Patients in the DOAC group reported greater satisfaction across several domains, including perceived treatment benefits, lower impact on daily life, and overall positive treatment effect. Event incidence rates (per 1,000 person-years) were higher with DOACs than with VKAs for stroke (1.75; 95% CI 1.05-2.92), ischemic stroke (1.78; 95% CI 1.06-3.00), acute myocardial infarction (1.64; 95% CI 0.97-2.79), and major bleeding (3.68; 95% CI 1.81-7.46). Conclusions: In routine primary care practice in Spain, patient profiles and treatment duration varied by oral anticoagulant type. These differences may partly explain the higher rates of stroke and major bleeding observed with DOACs versus VKAs, despite greater treatment satisfaction among patients receiving DOACs. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics Committee for Research with Medicines of Hospital Clinico San Carlos, at its meeting held on May 12, 2021 ,granted ethical approval I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced are available online at https://semergen.es/?seccion=investigacion&subSeccion=repositorioRacovir [https://semergen.es/?seccion=investigacion&subSeccion=repositorioRacovir](https://semergen.es/?seccion=investigacion&subSeccion=repositorioRacovir) Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.07.30.26359348v1 "Timing of Radiotherapy in Uveal Melanoma: A SEER-Based Comparison of Preoperative, Postoperative, and Intraoperative Approaches")[Next ](https://www.medrxiv.org/content/10.64898/2026.07.30.26359337v1 "Use of Federated Learning for validating and updating privacy-preserving decentralized multi-study prognostic models in Traumatic Brain Injury") Posted August 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/02/2026.07.30.26358911.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.07.30.26358911v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/02/2026.07.30.26358911.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Oral anticoagulation registry in patients with atrial fibrillation treated in Primary Care in clinical practice. The RACOVIR Study. Jose Polo Garcia, Rafael Manuel Mico Perez, Esperanza Garcia Gabriel, Juan Carlos Romero Vigara, Antonio Segura Fragoso, Aurora García Lerín, Valeria Kopytina, Carlos Santos Altozano medRxiv 2026.07.30.26358911; doi: https://doi.org/10.64898/2026.07.30.26358911 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.30.26358911v1%26text%3DOral%2520anticoagulation%2520registry%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520treated%2520in%2520Primary%2520Care%2520in%2520clinical%2520practice.%2520The%2520RACOVIR%2520Study. "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.30.26358911v1%26t%3DOral%2520anticoagulation%2520registry%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520treated%2520in%2520Primary%2520Care%2520in%2520clinical%2520practice.%2520The%2520RACOVIR%2520Study. "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.30.26358911v1%26title%3DOral%2520anticoagulation%2520registry%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520treated%2520in%2520Primary%2520Care%2520in%2520clinical%2520practice.%2520The%2520RACOVIR%2520Study.%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.30.26358911v1%26title%3DOral%2520anticoagulation%2520registry%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520treated%2520in%2520Primary%2520Care%2520in%2520clinical%2520practice.%2520The%2520RACOVIR%2520Study. "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.07.30.26358911) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.07.30.26358911v1&count=horizontal&via=&text=Oral%20anticoagulation%20registry%20in%20patients%20with%20atrial%20fibrillation%20treated%20in%20Primary%20Care%20in%20clinical%20practice.%20The%20RACOVIR%20Study.&counturl=www.medrxiv.org/content/10.64898/2026.07.30.26358911v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (594) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (887) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (322) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4677) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (465) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (402) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (631) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1593) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15645) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1176) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6875) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (714) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1034) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4848) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1411) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1699) * [Hematology](https://www.medrxiv.org/collection/hematology) (568) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1303) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16145) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1143) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (650) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (148) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (704) * [Neurology](https://www.medrxiv.org/collection/neurology) (7024) * [Nursing](https://www.medrxiv.org/collection/nursing) (357) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1056) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1206) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (988) * [Oncology](https://www.medrxiv.org/collection/oncology) (3509) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1014) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (381) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (432) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (453) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (135) * [Pathology](https://www.medrxiv.org/collection/pathology) (695) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1752) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (724) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (750) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5720) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9546) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2323) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1406) * [Respiratory Medicine](https://www.
## Related Clinical Research

- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)
- [Frailty prediction in heart failure with acute infection: role of thiazide diuretics and an interp](https://medichelpline.com/clinical-feed/plos-one-9-frailty-prediction-in-heart-failure-patients-with-acute-infections-the.md)
- [Cardiometabolic pathways mediating the effect of educational attainment on cardiovascular disease:](https://medichelpline.com/clinical-feed/medrxiv-13-cardiometabolic-pathways-linking-genetically-proxied-educational-attainment-to.md)
- [Caffeinated Coffee and Heart Health: How Much Coffee Is Safe Daily?](https://medichelpline.com/clinical-feed/aha-news-0-coffee-and-heart-health-how-many-cups-of-caffeinated-coffee-are-safe-to-drink.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.